AbbVie v. Prinston Pharmaceutical: Elagolix Sodium Patent Case Consolidated in Delaware
AbbVie filed a patent infringement action in the District of Delaware against Prinston Pharmaceutical, Solco Healthcare US, and Zhejiang Huahai Pharmaceutical over US11542239B2, covering elagolix sodium compositions and processes. After 384 days, the case was consolidated with six related ANDA actions under a single lead case.
AbbVie’s Elagolix ANDA Litigation Funnels Into One Delaware Action
AbbVie, Inc. filed this action on 2 June 2023 in the District of Delaware (Case No. 1:23-cv-00607) against Prinston Pharmaceutical, Inc., Solco Healthcare US, LLC, and Zhejiang Huahai Pharmaceutical Co., Ltd., asserting infringement of US11542239B2, which covers elagolix sodium compositions and processes. Elagolix is the active ingredient in Orilissa and Oriahnn, AbbVie’s products for endometriosis and uterine fibroids. The defendants are generic drug manufacturers and distributors associated with the Zhejiang Huahai supply chain, suggesting this action arose from an ANDA filing seeking approval to market a generic version of elagolix sodium.
The case closed on 20 June 2024 after 384 days, not through a merits decision or settlement, but through consolidation. By stipulation of all parties and court approval, this action was merged into a lead consolidated case, C.A. No. 22-1423-RGA-JLH, alongside six other related actions. All future filings now proceed under that single caption. The practical effect is that no separate judgment issued in this case — the dispute continues within the consolidated framework governed by the protective order already in place.
The consolidation of seven parallel ANDA cases into one proceeding is a common but strategically significant step in pharmaceutical patent litigation at Delaware District Court. It signals the breadth of AbbVie’s enforcement campaign around elagolix sodium and reduces duplicative litigation costs for all parties. What remains unknown from the public record of this specific docket is the claim construction posture, whether any defendants have asserted invalidity counterclaims, and the current trial schedule in the consolidated action.
Filing to Case Consolidated in 384 days
384 days — typical Delaware ANDA consolidation occurs within 6–18 months of filing
Case consolidated: what the transfer to the lead docket means for both parties
Consolidation under Fed. R. Civ. P. 42(a) — not a dismissal
Consolidation merges related actions sharing common questions of law or fact into a single proceeding. This case was not dismissed on the merits or resolved by settlement — it was absorbed into C.A. No. 22-1423-RGA-JLH alongside six other ANDA cases. All parties remain bound by the same protective order and amended complaint. The dispute over US11542239B2 continues; only the docket number changes.
Procedural consolidationAbbVie gains a unified litigation front across seven ANDA filers
Consolidation typically benefits a patent holder asserting the same patent against multiple generic filers. AbbVie can now coordinate claim construction, discovery, and trial strategy across all defendants in a single proceeding, reducing inconsistency risk and legal costs. The amended complaint filed as part of this stipulation suggests AbbVie updated its infringement allegations — potentially broadening or refining asserted claims before the consolidated schedule locks in.
Unified enforcementDefendants face a consolidated defence with shared discovery obligations
Prinston, Solco Healthcare, and Zhejiang Huahai now litigate alongside other generic defendants under a single case management order. This can reduce per-defendant costs but also requires coordination on invalidity and non-infringement strategies. Zhejiang Huahai’s involvement as the upstream API manufacturer adds supply-chain exposure. The Protective Order already in place governs confidential information across all consolidated parties.
Shared defence postureElagolix market entry for generics remains blocked pending consolidated trial
Until the consolidated action resolves — whether by trial, settlement, or consent judgment — the automatic 30-month stay under the Hatch-Waxman framework likely continues to block FDA approval of the defendants’ ANDAs. With seven generic challengers consolidated, the elagolix sodium market remains protected for AbbVie. The outcome of the lead case will bind all consolidated defendants, making the consolidated trial a high-stakes event for the entire generic pipeline.
Generic market entry delayedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AbbVie, Inc. | Company | Global biopharmaceutical company — holder of US11542239B2 (elagolix sodium)Search in Eureka ↗ |
| Defendant | Prinston Pharmaceutical, Inc. | Company | Generic pharma manufacturer/distributor trio: Prinston, Solco Healthcare, Zhejiang HuahaiSearch in Eureka ↗ |
| Co-Defendant | Solco Healthcare US, LLC | Company | Search in Eureka ↗ |
| Co-Defendant | Zhejiang Huahai Pharmaceutical Co., Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing AbbVie, Inc.Search in Eureka ↗ |
| Defendant counsel | Daniel Taylor | Attorney | Counsel for Prinston Pharmaceutical, Inc.Search in Eureka ↗ |
| Defendant law firm | Smith, Katzenstein & Jenkins LLP | Law Firm | Representing Prinston Pharmaceutical, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated order reflects a purely procedural resolution: no infringement finding, no validity ruling, and no damages assessment issued in this docket. The consolidation language confirms that the substantive dispute over US11542239B2 migrates intact to C.A. No. 22-1423-RGA-JLH. The amended complaint provision suggests AbbVie has refined its legal theory, which may affect how infringement is framed at the Markman and trial stages in the consolidated proceeding.
US11542239B2 — Elagolix Sodium Compositions and Processes
US11542239B2, filed under application number US16/519443, covers elagolix sodium compositions and their manufacturing processes. Elagolix sodium is a small-molecule GnRH receptor antagonist approved by the FDA as the active ingredient in Orilissa (endometriosis pain) and Oriahnn (uterine fibroid bleeding). The patent likely claims specific formulation parameters, polymorphic forms, or synthesis routes that define how elagolix sodium can be prepared or delivered — giving AbbVie enforceable exclusivity over generic replication of these methods.
For the pharmaceutical sector, US11542239B2 represents a secondary patent layer in AbbVie’s elagolix portfolio — the kind of composition or process patent that extends commercial exclusivity beyond initial compound protection. With seven ANDA filers now consolidated in Delaware, this patent is under simultaneous challenge by multiple generic manufacturers. Its validity and claim scope will effectively determine the entire generic entry timeline for elagolix sodium in the US market, making it one of the more commercially consequential patents in the women’s health therapeutic space.
Should you run an FTO analysis against US11542239B2?
Any company developing, manufacturing, importing, or distributing elagolix sodium — or formulating GnRH receptor antagonists with overlapping composition or process features — should treat US11542239B2 as a live enforcement risk. AbbVie has demonstrated willingness to pursue the full supply chain, including upstream API manufacturers like Zhejiang Huahai. R&D teams working on GnRH antagonist formulations or alternative elagolix sodium synthesis routes should commission an FTO review before entering the US market.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of US11542239B2 against your product specifications, flag design-around opportunities, and surface related AbbVie patents that may create additional enforcement risk. Eureka can also monitor the consolidated Delaware proceeding for claim construction rulings that could narrow or widen the patent’s effective scope — critical intelligence for timing any market entry decision.
Run a freedom-to-operate analysis on US11542239B2 to assess your product’s exposure
Run FTO in Eureka →Related Elagolix Sodium ANDA Patent Cases in Delaware District Court
The following cases involve elagolix sodium patent assertions by AbbVie in Delaware District Court and are consolidated under the same lead docket.
What this case signals for the pharmaceutical ANDA IP landscape
AbbVie’s consolidation of seven elagolix ANDA actions in Delaware is a textbook enforcement playbook — and a warning for generic entrants.
Multi-defendant ANDA consolidation is AbbVie’s strategic baseline for elagolix
Seven parallel cases merged into one signals a deliberate AbbVie strategy to neutralise generic competition through coordinated litigation rather than piecemeal defence. Generic filers entering the elagolix space should anticipate immediate Delaware action and consolidation into an already-mature proceeding with established protective orders and case management schedules.
Zhejiang Huahai’s presence raises upstream API supply-chain exposure
Including the Chinese API manufacturer as a defendant — alongside the US distributor (Solco Healthcare) and the ANDA filer (Prinston) — suggests AbbVie is pursuing the full vertical supply chain. Companies sourcing elagolix API from Zhejiang Huahai should review whether their own commercial activities create infringement exposure under US11542239B2.
AbbVie v Prinston — key questions answered
The case was closed on 20 June 2024 through consolidation, not a merits decision. After 384 days, the court approved a stipulation merging this action into lead case C.A. No. 22-1423-RGA-JLH alongside six other related ANDA cases. The dispute over US11542239B2 continues under the consolidated docket.
US11542239B2 covers elagolix sodium compositions and manufacturing processes. Elagolix sodium is the active ingredient in AbbVie’s Orilissa and Oriahnn products. The patent is asserted against generic manufacturers seeking ANDA approval to market elagolix sodium, with AbbVie claiming their formulation or process falls within the patent’s claims.
The case was consolidated because it shares common questions of law and fact with six other AbbVie elagolix ANDA cases pending in Delaware. Consolidation under Fed. R. Civ. P. 42(a) merges the actions for efficiency. No separate judgment issued — the infringement dispute continues in the lead case, C.A. No. 22-1423-RGA-JLH, binding all consolidated parties.
The defendants are Prinston Pharmaceutical, Inc. (the ANDA filer), Solco Healthcare US, LLC (US distributor), and Zhejiang Huahai Pharmaceutical Co., Ltd. (the Chinese API manufacturer). AbbVie named all three entities, suggesting it is pursuing the full vertical supply chain for the generic elagolix sodium product.
Consolidation does not terminate the Hatch-Waxman 30-month stay that typically arises from a Paragraph IV ANDA challenge. The stay — which blocks FDA approval of the generic ANDA — continues to run in the consolidated proceeding. Generic market entry for elagolix sodium remains blocked until the consolidated case resolves or the stay expires, whichever occurs first.
PatSnap Eureka searches patents and litigation data to answer instantly.